Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy
TEL AVIV, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals (NYSE and TASE: TEVA) today announced that Fitch Ratings Agency ('Fitch') has raised the Company's corporate credit rating to BB+, with a stable outlook; from BB.
Fitch's report cites Teva's progress in reducing debt and improving flexibility, expects continuous revenue growth from AUSTEDO and AJOVY, as well as Teva's biosimilar pipeline. In addition, Fitch mentions that Teva's focus on optimizing external spend, prioritizing resource allocation, and modernizing its organization is expected to lead to higher operating margins.
'We are proud to receive a second consecutive upgrade from Fitch within several months, especially coming on the heels of Moody's upgrade last Friday. This recognition reflects the strength of our financial discipline and the unwavering commitment of our teams. It's a powerful endorsement of our Pivot to Growth strategy and a clear signal of confidence in our future,' said Eli Kalif, Chief Financial Officer, Teva Pharmaceuticals.
About TevaTeva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a different kind of global biopharmaceutical leader, one that operates across the full spectrum of innovation to reliably deliver medicines to patients worldwide. For over 120 years, Teva's commitment to bettering health has never wavered. Today, the company's global network of capabilities enables its 37,000 employees across 57 markets to advance health by developing medicines for the future while championing the production of generics and biologics. We are dedicated to addressing patients' needs, now and in the future. Moving forward together with science that treats, inspired by the people we serve. To learn more about how Teva is all in for better health, visit www.tevapharm.com.
Teva Cautionary Note Regarding Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as 'should,' 'expect,' 'anticipate,' 'estimate,' 'target,' 'may,' 'project,' 'guidance,' 'intend,' 'plan,' 'believe' and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace, including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, to sustain and focus our portfolio of generic medicines, and to execute on our organizational transformation and to achieve expected cost savings; and other factors discussed in our Quarterly Report on Form 10-Q for the first quarter of 2025 and in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the section captioned 'Risk Factors' and 'Forward Looking Statements.' Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
Teva Media Inquiries
TevaCommunicationsNorthAmerica@tevapharm.com
Teva Investor Relations Inquiries
TevaIR@Tevapharm.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Why ABM Industries Stock Is Down Today
ABM delivered a quarter roughly in line with expectations, but the full-year forecast suggested some downside to expectations. Given the macro headwinds, investors seem to see more downside potential than upside from here, leading to a sell-off in the stock. 10 stocks we like better than Abm Industries › ABM Industries (NYSE: ABM) largely met Wall Street expectations for the quarter, but costs are on the rise and full-year guidance implies some risk of weakness compared to estimates. Investors are on the defensive, sending ABM shares down 13% as of noon ET. ABM supplies cleaning, parking, and other services to a wide range of facilities from office buildings to factories and airports. The company earned $0.86 per share in its fiscal second quarter ending April 30, a penny shy of expectations, on revenue that was in line at $2.1 billion. The quarter marked a return to organic revenue growth thanks to strength in the prime commercial office market. ABM also secured $1.1 billion in new bookings in the first half of its fiscal year, up 11%. Revenue growth was 3.4%, compared to a 3% rise in operating expenses and a 9% rise in selling, general, and administrative expenses. "We remain constructive on the outlook for our core markets, particularly high-quality office buildings, manufacturing and distribution facilities, commercial aviation, and microgrids," CEO Scott Salmirs said in a statement. "Further, projects delayed in the second quarter are expected to be realized in the third quarter." The quarter was fine, but investors appear to be reacting to the company leaving in place full-year guidance for earnings of $3.65 to $3.80 per share. At the midpoint that's below the $3.77 consensus. Investors came into this earnings season looking for more of an acceleration than what ABM could deliver and given the broader macro uncertainty there appears to be more downside risk than upside in the months to come. A slowdown in manufacturing, or layoffs that eat into office building occupancy, could hit results. Given the uncertainty, investors are likely wise to move to the sidelines right now. Before you buy stock in Abm Industries, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Abm Industries wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $674,395!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $858,011!* Now, it's worth noting Stock Advisor's total average return is 997% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Lou Whiteman has no position in any of the stocks mentioned. The Motley Fool recommends ABM Industries. The Motley Fool has a disclosure policy. Why ABM Industries Stock Is Down Today was originally published by The Motley Fool Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
30 minutes ago
- Yahoo
Circle IPO: Stock price today as stablecoin company makes long-awaited NYSE debut
The time has come for another highly anticipated arrival on the New York Stock Exchange (NYSE). Circle Internet Group, a stablecoin provider, is making its initial public offering today for $31 a share. Here's everything you need to know about Circle's IPO. Why you're catching the 'ick' so easily, according to science Why AI Is Making 1:1 Meetings Irrelevant Where are the wildfires in Canada? Maps pinpoint the location of fires and air-quality threats from smoke New York-based Circle, led by CEO Jeremy Allaire, is the issuer of USDC, a stablecoin tied to the U.S. dollar and the second-largest stablecoin globally. Circle also offers EURC, a stablecoin tied to the Euro. Circle set its share prices on Wednesday and plans to list its stock today, Thursday, June 5. The offer is expected to close the following day, Friday, June 6. Circle will trade its stock under the ticker CRCL. Circle will trade its shares on the NYSE. Circle's share price for the IPO is $31. The marketed estimate was $27 to $28. There will be 34 million shares of CRCL available. Circle is offering 14.8 million shares, while stockholders are selling 19.2 million shares. In addition, Circle is offering underwriters, like JPMorgan and Goldman Sachs, 30 days to purchase 5.1 million additional shares. The company is set to raise $1.1 billion in its IPO. Circle's current valuation is about $6.9 billion, but once all shares are diluted, it could increase to $8.1 billion. The stock market has experienced volatility under President Trump—especially in response to his 'Liberation Day' tariffs. However, PitchBook reports that some big names, such as Klarna, Discord, and Figma, are still expected to make IPOs this year. Klarna is the likeliest, with a 97% probability. Meanwhile, digital banking services startup Chime Financial is expected to list on the Nasdaq as soon as next week. This post originally appeared at to get the Fast Company newsletter: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
40 minutes ago
- Yahoo
Jim Cramer Says to 'Buy Dover (DOV) Right Now'
We recently published a list of . In this article, we are going to take a look at where Dover Corporation (NYSE:DOV) stands against other stocks that Jim Cramer discusses. Inquiring about Dover Corporation (NYSE:DOV), a caller asked if Cramer thinks that the stock will ever hit $222. He replied: 'I look wrong right now on Dover for the club… but I think I'm going to be right. Why? Because I think that Tobin is very smart, the CEO and the stock should never have been thrown back, 19 times earnings. It even went down when steel tariffs went on. I say enough is enough. Buy Dover right now, tomorrow morning.' A modern industrial equipment assembly line in motion. Dover (NYSE:DOV) produces items like pumps, flow meters, refrigeration systems, printing and coding equipment, vehicle lifts, winches, and fluid dispensing tools. Additionally, the company provides software and services used in fuel handling, industrial processing, climate control, and product traceability across various industries. During an episode of Squawk on the Street in April, Cramer commented: 'Okay so here's a good example of the craziness of this market. Dover reports. Dover did what RTX did the other day. They actually said okay listen the tariffs are hurting us. Okay, here's how they're hurting us. Stock was immediately down seven bucks. Down 7. And I was like I own it for my charitable trust and I'm like meumughmhgm . . .and then well people figured out, wait a second, they told the truth! Now the stock's up nice.' READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
